Lonza announces that Stefan Troger will be promoted to Site Manager of the Visp site, reporting to Harry Boot as of 1 April 2012. With this appointment leadership of the site and the Visp Challenge project will be merged into one.
Stefan Troger will succeed Stéphane Mischler, who successfully executed the role of Site Leader Visp over the past couple of years. After a long and impressive career and after more than 30 years of service Stéphane Mischler will retire in 2012. He will support Stefan Troger and the site management team until his retirement date in their pursuit of preparing the Visp site for the next decades. Stéphane Mischler will also continue to work with the pension fund of Lonza until his retirement.
Stefan Troger held several positions within Lonza over the past 19 years. Most recently he was Head of Biopharma Manufacturing in Visp and took over the leadership of the project “Visp Challenge”. Visp Challenge is designed to map out the future set-up of the Visp site. In the next weeks Stefan Troger and his team will further stream-line the Visp organization to meet and support the business need.
“With Stefan Troger we have the possibility to unify the site leadership of the Visp site and project management of Visp Challenge. Our Visp site is confronted with major challenges in regards to currency, markets and technologies. The Visp Challenge project is working on two ends: increase productivity (lower cost and higher output from existing plants) in the short- and midterm and improve the product portfolio to secure the future of Visp in the long-term. Stefan Troger and his team have the right skill sets and the necessary level of positive energy to make this happen”, comments Lonza CEO Stefan Borgas.
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also the world leader in microbial control providing innovative, chemistry-based and related solutions to destroy or to selectively inhibit the growth of harmful microorganisms. Its activities encompass the areas of water treatment, personal care, health and hygiene, industrial preservation, materials protection, and wood treatment. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition and agro markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza is not subject to the SGX-ST’s continuing listing requirements. Lonza is subject to the listing rules of the SIX Swiss Exchange, which do not have specific requirements equivalent to the listing rules of the SGX-ST in respect of interested person transactions, acquisition and realizations, and delisting. In 2010, the company had sales of CHF 2.680 billion. Further information can be found at www.lonza.com
Lonza Group Ltd
Head of Corporate Communications
Tel +41 61 316 8798
Fax +41 61 316 9798
Lonza Group Ltd
Tel +41 61 316 8540
Fax +41 61 316 9540
Lonza Group Ltd
Tel +1 201 316 9413
Fax +1 201 696 3533